NCT07066683

Brief Summary

Charcot-Marie-Tooth disease type 1A is the most common form of inherited neuropathy that causes peripheral nerve damage in all four limbs. In addition to the well-known distal motor and sensory symptoms, fatigue is one of the most common symptoms reported by patients. However, there is very little scientific data on this topic. Fatigue is associated with changes in mobility and quality of life. This study investigates the magnitude and impact of fatigue on patients' sensory-motor function and mobility (standing and walking). Fatigue is a complex phenomenon. It is therefore essential to assess all the factors that may be at the origin of this symptom (perceived fatigue and fatigability) using innovative and robust assessment methods. These methods are based on quantitative non-invasive neurophysiologic measures (electromyography and transcranial magnetic stimulation). The patients can quantify and identify more precisely the origin of fatigability (peripheral and central). This objective approach needs to be combined with the usual methods of measuring fatigue using valid and reliable patient-reported outcome measures. A quantitative measure of movement during walking must also be included to assess changes in fatigue during functional movement. To quantify the proportion of fatigue associated with CMT1A, the investigators chose to compare data from patients with those of healthy subjects matched for age, height and lean body mass. A better understanding of the role of fatigue in limiting walking and balance capacities in these patients will allow the investigators to refine the inpatient and outpatient management.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
21mo left

Started Feb 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Feb 2026Feb 2028

First Submitted

Initial submission to the registry

March 19, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 15, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

February 20, 2026

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2026

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Expected
Last Updated

February 19, 2026

Status Verified

July 1, 2025

Enrollment Period

Same day

First QC Date

March 19, 2025

Last Update Submit

February 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Fatigability profile

    Difference in isometric force developed by the knee extensors (assessment of overall neuromuscular fatigue) before and after a tiring exercise (stress test), during a maximum voluntary contraction, expressed in N.m-1, assessed on an isokinetic dynamometer (CONTREX®), compared between patients with mCMT1A and healthy volunteers.

    7 days

Study Arms (2)

Charcot Marie Tooth type 1A

EXPERIMENTAL

CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level * Quality of life

Other: CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION

Healthy subjects matched for age, height and lean body mass.

ACTIVE COMPARATOR

Identical to patient, except for Charcot-Marie-Tooth specific tests

Other: CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION

Interventions

Tip: Ensure that this name matches the name used in the associated Arm Description. CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength and power * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls

Charcot Marie Tooth type 1AHealthy subjects matched for age, height and lean body mass.

Eligibility Criteria

Age18 Years - 74 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years and \< 75 years
  • Patient with mCMT1A confirmed by genetic analysis (based on data recorded in the patient file)
  • Patient able to walk a minimum of 200 metres without a break, with or without equipment and/or technical aids (collected during questioning)
  • Patient able to get on and off a cycloergometer safely without assistance or with minimal assistance
  • Patient affiliated to a health insurance scheme or beneficiary of such a scheme
  • Age ≥ 18 years and \< 75 years
  • Subject affiliated to or benefiting from a health insurance scheme
  • Subject who has had a cardiological work-up prior to stress testing (ECG and cardiac ultrasound less than 6 months old) or for whom a work-up is scheduled prior to the procedure.

You may not qualify if:

  • Patients with all other forms of neuropathy (HNPP, other types of CMT, secondary neuropathies)
  • Patients with any of the following
  • An associated neurological disease other than mCMT1A
  • Severe joint disease of the lower limbs
  • Contraindication to isokinetic testing
  • Contraindication to an exercise stress test and exercise reconditioning program
  • A contraindication to Transcranial Magnetic Stimulation (TMS) : epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc.
  • Pregnant or breastfeeding or planning to become pregnant within the next 4 months
  • BMI \> 35 kg/m2
  • Patient unable to give informed consent, unable to understand informed information
  • Subject under court protection
  • Subject under guardianship or curatorship
  • History of neurological disease
  • Severe joint damage in the lower limbs
  • Any of the following
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pôle de médecine physique et de réadaptation, Hôpital de Hautepierre, Strasbourg Centre de référence des maladies neuromusculaires, Institut Universitaire de Réadaptation Clémenceau, Strasbourg

Strasbourg, 67000, France

Location

MeSH Terms

Interventions

Restraint, Physical

Intervention Hierarchy (Ancestors)

Behavior ControlTherapeuticsImmobilizationInvestigative Techniques

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2025

First Posted

July 15, 2025

Study Start

February 20, 2026

Primary Completion

February 20, 2026

Study Completion (Estimated)

February 1, 2028

Last Updated

February 19, 2026

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations